Journal article
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
SK Leang, S Kwok, SG Sullivan, S Maurer-Stroh, A Kelso, IG Barr, AC Hurt
Influenza and Other Respiratory Viruses | Published : 2014
DOI: 10.1111/irv.12187
Abstract
Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir..
View full abstractGrants
Awarded by A*STAR Singapore
Funding Acknowledgements
The authors thank all the laboratories that submit specimens and isolates to the Melbourne WHO CCRRI for antiviral sensitivity testing. Peramivir (BCS-1812) was kindly provided by BioCryst Pharmaceuticals Inc, NC, USA and, laninamivir (R-125489) was kindly provided by Daiichi-Sankyo, Tokyo, Japan. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. This work was partially supported by the Australian NHMRC and A*STAR Singapore through the joint grant 12/1/06/24/5793 to ACH and SMS.